| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | elocalcitol | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.016 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |